BioCentury
ARTICLE | Clinical News

FDA approves traveler's diarrhea drug from Cosmo

November 30, 2018 8:34 PM UTC

FDA approved Aemcolo rifamycin from Cosmo Pharmaceuticals N.V. (SIX:COPN) to treat travelers' diarrhea caused by non-invasive strains of Escherichia coli.

The company said it will launch the drug next quarter. ...

BCIQ Company Profiles

Cosmo Pharmaceuticals N.V.